The COVID-19 cases in the United States have crossed 11 million, with the latest one million cases coming at breakneck speed in the last week alone.
![US COVID-19 Cases Cross 11 Million US COVID-19 Cases Cross 11 Million](https://images.medindia.net/health-images/1200_1000/coronavirus-pollution-mask.jpg)
‘COVID-19 in the US: The seven-day rolling average for daily new deaths was more than 1,000 this weekend, ticking higher than in preceding weeks.’
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
North Dakota is in such dire straits that hospitals there are allowing infected but asymptomatic nurses to treat Covid-19 patients. ![twitter](https://images.medindia.net/icons/news/social/twitter.png)
![facebook](https://images.medindia.net/icons/news/social/facebook.png)
![whatsapp](https://images.medindia.net/icons/news/social/whatsapp.png)
![linkedin](https://images.medindia.net/icons/news/social/linkedin.png)
![pinterest](https://images.medindia.net/icons/news/social/pinterest.png)
But outside, in malls and grocery stores, Americans are out in full force - a stark contrast to the grim public health crisis that continues to hammer the country.
Based on current trajectory, America is hurtling towards an ominous coronavirus toll of more than 4,00,000 by next Spring, according to new projections from a predictive model used often by data crunchers in Donald Trump's White House coronavirus task force.
The Institute for Health Metrics and Evaluation (IHME) at the University of Washington is predicting a total of 438,941 deaths in America by March 1, 2021.
Dr. Anthony Fauci, who serves on the Trump coronavirus task force, and President-elect Biden are pleading with Americans to wear masks and socially distance until the vaccines arrive - very soon.
Advertisement
The US is working with a portfolio of six vaccines, using three different platform technologies and two candidates from each platform: messenger RNA, live viral vectors and recombinant protein.
Advertisement
One of them - Pfizer - announced that it has achieved 90 per cent efficacy. The company hopes to file for emergency use authorisation as soon as its final efficacy results arrive in the third week of November.
Source-IANS